Literature DB >> 11206763

Comparison of cardiovascular risk and lipid profiles in patients undergoing aortic valve surgery versus those undergoing coronary artery bypass grafting.

G M Novaro1, G L Pearce, D L Sprecher, B P Griffin.   

Abstract

BACKGROUND AND AIM OF THE STUDY: Hyperlipidemia is a risk factor for the progression of coronary artery disease, and possibly also valvular aortic stenosis. Thus, patients with aortic stenosis, coronary disease (or both) might be expected to have more abnormal lipid profiles than those without these two conditions.
METHODS: The lipid profiles of patient subsets undergoing aortic valve replacement (AVR) with or without concomitant coronary artery bypass grafting (CABG), as well as those undergoing isolated CABG, between 1987 and 1997 were analyzed retrospectively. Four surgical groups were identified: AVR for aortic regurgitation (n = 370); AVR for predominant aortic stenosis (n = 1,072); AVR for aortic stenosis (AS) with CABG (n = 914); and isolated CABG (n = 11,156). The complete fasting lipid profiles of patients were collected, analyzed by group, and compared.
RESULTS: Analysis by Spearman's correlation showed that total cholesterol levels, triglycerides and low-density lipoproteins (LDL-C) were modestly, yet significantly, increased in each successive group, while high-density lipoproteins were decreased. AS patients undergoing isolated AVR had significantly higher total cholesterol (215 versus 201 mg/dl; p <0.0001), triglycerides (125 versus 104 mg/dl; p <0.0001) and LDL-C (139 versus 132 mg/dl; p = 0.003) than those undergoing AVR for aortic regurgitation. Total cholesterol >200 mg/dl was significantly associated with AS, even after adjusting for differences in age, sex, diabetes mellitus and hypertension, with an odds ratio of 1.5 (95% confidence interval, 1.2-2.0; p = 0.001).
CONCLUSION: Progressively abnormal lipid profiles are associated with AS and coronary disease in patients undergoing AVR. This evidence helps to extend the link between dyslipidemia and AS in a large consecutive series of patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11206763

Source DB:  PubMed          Journal:  J Heart Valve Dis        ISSN: 0966-8519


  5 in total

1.  Risk factors for progression of calcific aortic stenosis and potential therapeutic targets.

Authors:  Ashvin R Kamath; Ramdas G Pai
Journal:  Int J Angiol       Date:  2008

Review 2.  Statins and aortic stenosis progression: are biologic targets still an option?

Authors:  Ramdas G Pai
Journal:  Curr Cardiol Rep       Date:  2005-11       Impact factor: 2.931

3.  Differing relationship between hypercholesterolemia and a bicuspid aortic valve according to the presence of aortic valve stenosis or aortic valve regurgitation.

Authors:  Masahiro Endo; Akihiro Nabuchi; Hiroshi Okuyama; Yasushi Muto; Susumu Hiranuma; Takuya Miyazaki; Joji Hosokawa; Yoshihisa Enjoji; Yumi Shimura; Osamu Hashimoto
Journal:  Gen Thorac Cardiovasc Surg       Date:  2015-06-02

4.  Degenerative valve disease and bioprostheses: risk assessment, predictive diagnosis, personalised treatments.

Authors:  Kristina Yeghiazaryan; Dirk Skowasch; Gerhard Bauriedel; Hans H Schild; Olga Golubnitschaja
Journal:  EPMA J       Date:  2011-04-03       Impact factor: 6.543

5.  Augmented osteogenic responses in human aortic valve cells exposed to oxLDL and TLR4 agonist: a mechanistic role of Notch1 and NF-κB interaction.

Authors:  Qingchun Zeng; Rui Song; Lihua Ao; Dingli Xu; Neil Venardos; David A Fullerton; Xianzhong Meng
Journal:  PLoS One       Date:  2014-05-08       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.